




PHARMACEUTICAL 2021

Catalent Inc.
Rank 196 of 402





RealRate

PHARMACEUTICAL 2021

Catalent Inc.
Rank 196 of 402

Catalent®

The relative strengths and weaknesses of Catalent Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Catalent Inc. compared to the market average is the variable Intangible Assets, increasing the Economic Capital Ratio by 72% points. The greatest weakness of Catalent Inc. is the variable Other Liabilities, reducing the Economic Capital Ratio by 111% points.

The company's Economic Capital Ratio, given in the ranking table, is 103%, being 56% points above the market average of 47%.

Input Variable	Value in 1000 USD
Assets, Current	2,293,000
Cost of Goods Sold	2,111,000
Intangible Assets	3,359,300
Liabilities, Current	893,200
Liabilities, Non-Current	203,600
Other Assets	223,400
Other Compr. Net Income	-32,400
Other Expenses	45,200
Other Liabilities	3,174,300
Other Net Income	-139,500
Other Revenues	3,094,300
Property and Equipment	1,900,800
Research and Development	0
Selling, General and Administrative Expense	577,900

Output Variable	Value in 1000 USD
Assets	7,776,500
Liabilities	4,271,100
Expenses	2,734,100
Revenues	3,094,300
Stockholders Equity	3,505,400
Net Income	220,700
Comprehensive Net Income	204,500
Economic Capital Ratio	103%